重藥控股(000950.SZ):上半年淨利降35.31%至3億元
格隆匯 8 月 24日丨重藥控股(000950.SZ)披露2020年半年度報告,實現營業收入170.65億元,同比增長5.30%;歸屬於上市公司股東的淨利潤3億元,同比下降35.31%;歸屬於上市公司股東的扣除非經常性損益的淨利潤2.93億元,同比下降32.05%;基本每股收益0.17元。
1、進一步健全全國商業網絡佈局。報告期內,成功布局安徽、吉林、內蒙三地,有效夯實全國戰略佈局;天士營銷商業併購項目、四川人福項目即將落地;有序推進其他省份併購項目。
2、在新一輪帶量採購中,集採模式效果繼續凸顯。31個品規中30個落户公司,獨家點配佔比近60%;25個首批GPO續標品種100%落户集團總部;在中國上市的25個新藥實現100%落户;促成中國醫藥-重慶醫藥商業聯合體企業在重點供應商實現一、二級開户23家。
3、“醫藥+互聯網”探索成效顯著。報告期內,公司持續踐行“兩網互動”戰略,在“醫藥+互聯網”方面展現新的成果。自主開發的電子處方平台在160餘家藥房上線,開具處方1萬餘張;與重慶市急救中心、重醫附二院、永川醫院互聯網醫院合作,有效拓寬處方藥銷售渠道,增強與醫院的粘性;和平藥房啟動直播銷售、上線微商城,探索線上線下相結合的全渠道運營。
4、醫藥研發板塊取得較大進展。穩步推進新品研發,有望實現自2021年起持續有創新產品上市的良性發展節奏。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.